PMC:7228307 / 574-1167
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 20 | 366-370 | Gene | denotes | FcγR | Gene:2213 |
| 21 | 9-13 | Gene | denotes | FcγR | Gene:2213 |
| 26 | 106-112 | Disease | denotes | cancer | MESH:D009369 |
| 27 | 553-560 | Disease | denotes | cancers | MESH:D009369 |
| 28 | 562-583 | Disease | denotes | inflammatory diseases | MESH:D007249 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T5 | 113-118 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T6 | 128-136 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T7 | 271-280 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T2 | 106-112 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
| T3 | 562-583 | Disease | denotes | inflammatory diseases | http://purl.obolibrary.org/obo/MONDO_0021166 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T9 | 9-11 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
| T10 | 113-118 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T11 | 323-326 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T12 | 341-342 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T13 | 366-368 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T4 | 23-31 | Chemical | denotes | effector | http://purl.obolibrary.org/obo/CHEBI_35224 |
| T5 | 248-262 | Chemical | denotes | macromolecules | http://purl.obolibrary.org/obo/CHEBI_33839 |
LitCovid-sample-PD-IDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T5 | 113-118 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cells |
| T6 | 575-583 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | diseases |
LitCovid-sample-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 248-262 | Chemical | denotes | macromolecules | http://purl.obolibrary.org/obo/CHEBI_33839 |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 20 | 366-370 | Gene | denotes | FcγR | Gene:2213 |
| 21 | 9-13 | Gene | denotes | FcγR | Gene:2213 |
| 26 | 106-112 | Disease | denotes | cancer | MESH:D009369 |
| 27 | 553-560 | Disease | denotes | cancers | MESH:D009369 |
| 28 | 562-583 | Disease | denotes | inflammatory diseases | MESH:D007249 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T8 | 60-294 | Sentence | denotes | This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. |
| T9 | 295-511 | Sentence | denotes | The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. |
LitCovid-sample-PD-FMA
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T5 | 113-118 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T6 | 128-136 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T7 | 271-280 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
LitCovid-sample-PD-GO-BP-0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 158-170 | http://purl.obolibrary.org/obo/GO_0006909 | denotes | phagocytosis |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 106-112 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
| T2 | 562-583 | Disease | denotes | inflammatory diseases | http://purl.obolibrary.org/obo/MONDO_0021166 |
LitCovid-sample-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 106-112 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sample-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 158-170 | http://purl.obolibrary.org/obo/GO_0006909 | denotes | phagocytosis |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 158-170 | http://purl.obolibrary.org/obo/GO_0006909 | denotes | phagocytosis |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T8 | 60-294 | Sentence | denotes | This is most evident for antibodies targeting cancer cells inducing antibody‐dependent killing or phagocytosis but is also true to some degree for the mAbs that neutralize or remove small macromolecules such as cytokines or other Igs. |
| T9 | 295-511 | Sentence | denotes | The use of mAb therapeutics has also revealed a “scaffolding” role for FcγR which, in different contexts, may either underpin the therapeutic mAb action such as immune agonism or trigger catastrophic adverse effects. |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 106-112 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |